29 Oct 2026

Moldova's Ministry of Health (Ministerul Sănătății) has outlined a staged reform of pharmaceutical price regulation following a review of market availability and spending between 2021 and 2025. The proposals, published on 27 October, address manufacturer prices, distribution mark-ups and the treatment of non-prescription medicines.

Current rules regulate prices for prescription and non-prescription medicines, including tiered wholesale and retail mark-ups. The Ministry argues that this structure has not prevented higher non-prescription prices or the disappearance of lower-priced products. Its review found a net reduction of 708 medicine presentations sold in pharmacies between 2021 and 2025.

The first stage would revise how manufacturer prices are set using reference countries with markets comparable to Moldova. A new pharmacy law would then broaden permitted pharmacy formats, including mobile outlets. Subsequent regulations would replace tiered mark-ups and introduce controlled liberalisation for selected non-prescription medicines.

Essential, reimbursed and centrally purchased medicines would retain price controls. The Ministry says existing regulation will remain in force while draft instruments undergo consultation and approval.

Its preliminary modelling suggests annual expenditure could fall by up to MDL375 million after all three stages. About MDL199 million would arise from the proposed rule changes, with the balance attributed to revised external reference prices. These estimates depend on final legal provisions and actual supplier pricing responses.

Source: Ministry of Health, Moldova
Link: Schimbările propuse de Ministerul Sănătății pentru a opri dispariția medicamentelor, pentru a asigura prezența tratamentelor necesare și pentru a reduce cheltuielile populației și ale bugetului de stat la medicamente cu 375 de milioane de lei pe an (Ministry proposals to sustain medicine availability and reduce medicine expenditure by up to MDL375 million annually)
Date: 27 October 2026